The 2 FDA-approved COVID-19 vaccines are similarly effective but also very different in a number of ways that will affect distribution.
The US Food and Drug Administration has approved for emergency use 2 vaccines against the coronavirus disease 2019 (COVID-19), one from Pfizer-BioNTech (December 11, 2020) and the other from Moderna (December 18, 2020).
The vaccines are very similar in terms of efficacy and both require a priming dose followed by a booster a few weeks later. But there are vast differences in aspects like cold chain storage and even minimum purchase amount required that are already impacting who likely will receive which vaccine.
The short slide show below summarizes a comparison of features published on the web site STAT.